Table 1.
Summary of endovascular stenting series for the treatment of intracranial atherosclerosis published after SAMMPRIS.
| Series | Year | Type of stent | Number of patients (lesions) | Minimum arterial stenosis | Technical success rate | Mean/median clinical follow-up duration (months) | Rate of postprocedural ischemia (ipsilateral) | Rate of postprocedural ischemia (all) | Rate of symptomatic in-stent restenosis |
|---|---|---|---|---|---|---|---|---|---|
| Gandini et al. [20] | 2013 | Wingspan | 21 (42) | 70% | 100% | 20 | 4.8% | 4.8% | 0 |
| Jin et al. [33] | 2013 | Multiple1 | 226 (233) | NR | NR | 39 | 11.6% | 11.6% | 5.2% |
| Park et al. [18] | 2013 | Cypher | 11 (11) | 50% | 100% | 67 | 0 | 0 | 0 |
| Rohde et al. [21] | 2013 | Multiple2 | 100 (100) | 50% | 94.0% | 1 | NR | 25% | NR |
| Yu et al. [17] | 2013 | Wingspan | 95 (95) | 70% | 93.7% | 41 | 3.1% in 30 days, 0% from 30 days to 1 year | 9.5% in 1 year | NR |
| Zhang et al. [19] | 2013 | Wingspan | 61 (61) | 70% | 98.4% | 24 | 10.0% | 11.7% | 3.3% |
| Jiang et al. [28] | 2012 | Multiple3 | 637 (670) | 50% | 94.6% | NR | 5.8% at 30 days, 13.7% overall | 5.8% at 30 days, 13.7% overall | 11.1% |
| Kim et al. [22] | 2012 | Multiple4 | 77 (85) | 50% | 87.1% | 29 | 7.7% | 9.2% | 3.1% |
| Kurre et al. [31] | 2012 | Multiple5 | 397 (409) | 50% | 98.0% | NR | 11.6% | NR | |
| Li et al. [30] | 2012 | Wingspan | 30 (31) | 70% | 100% | 18 | 13.3% | 16.7% | 5.3% |
| Mohammadian et al. [24] | 2012 | Multiple6 | 34 (34) | 70% | 97.0% | 15 | 2.9% | 5.8% | 0 |
| Tarlov et al. [26] | 2012 | Multiple7 | 41 (41) | 50% | 100% | 14 | NR | 20.0% | 7.5% |
| Vajda et al. [29] | 2012 | Enterprise | 189 (209) | 50% | 99.5% | 7 | 2.3% | 7.7% | 2.3% |
| Vajda et al. [23] | 2012 | Coroflex Please | 95 (106) | 50% | 93.4% | 16 | 1.9% | 3.8% in 30 days, 0.9% after 30 days | 0 |
| Yu et al. [27] | 2012 | Wingspan | 57 (57) | 50% | 93.0% | NR | NR | 8.8% | NR |
| Zhang et al. [25] | 2012 | Wingspan | 53 (53) | 50% | 98.1% | 18 | 6.0% | 10.0% | 4.0% |
| Costalat et al. [32] | 2011 | Wingspan | 60 (63) | 50% | 95.2% | 13 | 6.3% | 6.3% | 2.0% |
| Park et al. [34] | 2011 | FlexMaster | 12 (14) | 70% | 100% | 9 | 0 | 0 | 0 |
NR: not reported.
1Multiple stents were used in this study including Wingspan (Boston Scientific), Apollo (MicroPort Medical), and coronary balloon-expandable stents.
2Multiple stents were used in this study including AVE (Medtronic), Neurolink (Guidant), Neuroform (Boston Scientific), and Wingspan (Boston Scientific) stents.
3Multiple stents were used in this study including Vision (Abbott), Mini-Vision (Abbott), Penta (Abbott), Taxus Express (Boston Scientific), Cypher (Cordis Corp), S70 (Medtronic), Driver (Medtronic), Apollo (MicroPort Medical), BiodivYsio (Biocompatibles), and Wingpan (Boston Scientific) stents.
4Multiple stents were used in this study including Endeavor (Medtronic), Vision (Abbott), FlexMaster (Abbott), Arthos pico (AMG International), Neuroform (Boston Scientific), Tsunami (Terumo), and Driver (Medtronic) stents.
5Multiple stents were used including Wingspan (Boston Scientific), LEO (BALT Extrusion), Neuroform (Boston Scientific), Enterprise (Cordis Corp), Xpert (Abbott), Pharos (Micrus), BOA (BALT Extrusion), Apollo (MicroPort Medical), Arthos (AMG), AVE S660 and S670 (Medtronic) BX Sonic and Velocity (Cordis Corp), Cerebrence (Medtronic), Coroflex blue (Braun), Driver (Medtronic), Endeavour (Medtronic), FlexMaster (Abbott), INX (Medtronic), Lekton Motion (Biotronik), Multi-Link (Abbott), S7 (Medtronic), Taxus Express and Liberte (Boston Scientific), Tecnic carbostent (Sorin Biomedica), and Tsunami Gold (Terumo) stents.
6Multiple stents were used including balloon-mounted, coronary bare metal stent for internal carotid artery stenosis, and self-expanding stents for middle cerebral artery stenosis.
7Multiple stents were used including Wingspan (Boston Scientific), AVE (Medtronic), ACS, Voyager (Abbott), Vision (Abbott), Palmaz-Schatz (Cordis Corp), Multilink (Abbott), and other Guidant and Medtronic stents.